M3302835
Ipilimumab , 95%,5mg/mLinBuffersolution , 477202-00-9
| Pack Size | Price | Stock | Quantity |
| 1mg | RMB4280.00 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| form | Liquid |
| color | Colorless to light yellow |
Description and Uses
Ipilimumab is a CTLA-4 blocking antibody that was approved by the U.S. FDA in March 2011 for the treatment of unresectable or metastatic melanoma. Therefore, ipilimumab has an indirect effect on tumors that is mediated through blockade of CTLA-4 negative signaling and augmentation of T-cell activity. It is one of a handful of immunostimulatory drugs (e.g., aldesleukin and interferon alfa-2b) now approved for cancer therapy.
Treatment of oncology disease and HIV infection.